US Commercial Plans Increase Choice Of Biosimilar And Originator Products; Market Net Prices Decrease
Health Affairs · 2024
DOI: 10.1377/hlthaff.2023.01532 ↗Kurz gefasst
Fachartikel in der Zeitschrift Health Affairs, 2024. Verfasst von Molly T Beinfeld und 4 weiteren Autor:innen. Beteiligte Einrichtung: Molly T. Beinfeld (mbeinfeld@tuftsmedicalcenter.org), Tufts University, Boston, Massachusetts. Hauptthemen laut MEDLINE: Biosimilar Pharmaceuticals, Drug Costs. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 4 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Molly T. Beinfeld (mbeinfeld@tuftsmedicalcenter.org), Tufts University, Boston, Massachusetts.
- Fariel LaMountain, Tufts University.
- William Wong, Genentech, Inc., San Francisco, California.
- Eunice Kim, Genentech, Inc.
- James D. Chambers, Tufts University.
Zitieren
APA
Beinfeld, M. T., LaMountain, F., Wong, W., Kim, E., & Chambers, J. D. (2024). US Commercial Plans Increase Choice Of Biosimilar And Originator Products; Market Net Prices Decrease. Health Affairs. https://doi.org/10.1377/hlthaff.2023.01532
Vancouver
Beinfeld MT, LaMountain F, Wong W, Kim E, Chambers JD. US Commercial Plans Increase Choice Of Biosimilar And Originator Products; Market Net Prices Decrease. Health Affairs. 2024. doi:10.1377/hlthaff.2023.01532
BibTeX
@article{Beinfeld2024,
author = {Beinfeld, Molly T and LaMountain, Fariel and Wong, William and Kim, Eunice and Chambers, James D},
title = {US Commercial Plans Increase Choice Of Biosimilar And Originator Products; Market Net Prices Decrease},
journal = {Health Affairs},
year = {2024},
doi = {10.1377/hlthaff.2023.01532}
}
EUVIMED